The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1571
ISSUE 1571
May 6, 2019
Insulins for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
May 6, 2019 (Issue: 1571)
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
... more
- American Diabetes Association. Standards of medical care in diabetes – 2019. Diabetes Care 2019; 42 (Suppl):S1.
- Drugs for type 2 diabetes. Med Lett Drugs Ther 2017; 59:9.
- Insulin detemir (Levemir), a new long-acting insulin. Med Lett Drugs Ther 2006; 48:54.
- L Meneghini et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15:729.
- Another insulin glargine (Basaglar) for diabetes. Med Lett Drugs Ther 2017; 59:3.
- Concentrated insulin glargine (Toujeo) for diabetes. Med Lett Drugs Ther 2015; 57:69.
- Insulin degludec (Tresiba) – a new long-acting insulin for diabetes. Med Lett Drugs Ther 2015; 57:163.
- C Wysham et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 2017: 318:45.
- MC Riddle et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080.
- J Rosenstock et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009; 52:1778.
- K Horvath et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (review). Cochrane Database Syst Rev 2007; 2:CD005613.
- K Hermansen et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29:1269.
- KJ Lipska et al. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn (NPH) insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA 2018; 320:53.
- J Luo et al. Implementation of a health plan program for switching from analogue to human insulin and glycemic control among Medicare beneficiaries with type 2 diabetes. JAMA 2019; 321:374.
- KJ Lipska et al. Insulin analogues for type 2 diabetes. JAMA 2019; 321:350.
- Fiasp - another insulin aspart formulation for diabetes. Med Lett Drugs Ther 2018; 60:6.
- In brief: another insulin lispro (Admelog) for diabetes. Med Lett Drugs Ther 2018; 60:e109.
- SR Singh et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180:385.
- Rapid-acting insulin analogs. Med Lett Drugs Ther 2009; 51:98.
- Insulin glulisine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther 2006; 48:33.
- E Mannucci et al. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009; 11:53.
- S Heller et al. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes 2013; 5:482.
- An inhaled insulin (Afrezza). Med Lett Drugs Ther 2015; 57:34.
- Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes. Med Lett Drugs Ther 2017; 59:147.
- Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017; 59:19.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Insulins for Type 2 Diabetes
Article code: 1571a
Electronic, downloadable article - $45
Article code: 1571a
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian